On Oct. 25, 2023, Invitae announced findings from the largest study to date on uncertain results from hereditary disease genetic testing. Published in JAMA Network Open, the study evaluated data from more than 1.6 million individuals undergoing multi-gene panel testing across various clinical specialty areas.
On October 12, 2023, Invitae announced results of its collaborative study on universal hereditary cancer genetic testing in all patients with breast cancer in a rural population in the Annals of Surgical Oncology. Conducted in collaboration with The Outer Banks Hospital in North Carolina from 2019 to 2022, the study analyzed the implementation of universal hereditary cancer genetic testing in all patients with breast cancer, as recommended by the American Society of Breast Surgeons guidelines in 2019. The results reaffirm the previous findings of Whitworth et al. that universal hereditary cancer genetic testing improves patient outcomes and shows testing-based de-escalation of therapy which may curtail treatment costs.
On October 03, 2023, Invitae announced it gained FDA market authorization for its Common Hereditary Cancers Panel. This represents the first broad panel that is used to identify germline variants associated with hereditary cancer to gain market authorization from the FDA.
On August 15, 2023, Invitae announced
findings from its PROCLAIM trial, published in European Urology
Oncology, showing that almost half of prostate cancer patients with
clinically actionable pathogenic/likely pathogenic germline variants could be missing out on genetics-informed care due to restrictive
criteria for genetic testing.
On April 13, 2023, Invite announced new research published in Nature
describing the first use of the company's personalized cancer
monitoring (PCM) platform to demonstrate the utility of ctDNA as a
biomarker for cancer recurrence in a large cohort of patients with stage
I-III non-small-cell lung cancer followed for up to five
years.
On March 22, 2023, Invite and Deerfield Management Company announced a partnership to advance genetics-based drug discovery and development in rare disease.
On March 06, 2023, Invitae announced
that its Personalized Cancer Monitoring (PCM™) assay, which helps detect
minimal residual disease (MRD) in patients, has obtained its first
commercial coverage in all solid tumors by Blue Shield of California.
----------------------------------------------------------------------------------------------------------------------
Below is a summary of Invitae's US patent application publications in 2023/24 (as of 01/10/2024):
For accuracy and details, please review the individual patent applications at Google patent search or US patent office website.
